Arca
Skip to content

PCSK9: Proprotein convertase subtilisin/kexin type 9

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Crucial player in the regulation of plasma cholesterol homeostasis.

  • Drugs that act on it: 9
  • With a US drug page: 3
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
AlirocumabApprovedSubtilisin/kexin type 9 inhibitorInhibitor—
EvolocumabApprovedSubtilisin/kexin type 9 inhibitorInhibitor—
LerodalcibepApprovedSubtilisin/kexin type 9 inhibitorInhibitor—
Bococizumab—Subtilisin/kexin type 9 inhibitorInhibitor—
Frovocimab—Subtilisin/kexin type 9 inhibitorInhibitor—
Ongericimab—Subtilisin/kexin type 9 inhibitorInhibitor—
Ralpancizumab—Subtilisin/kexin type 9 inhibitorInhibitor—
RG-7652—Subtilisin/kexin type 9 inhibitorInhibitor—
Tafolecimab—Subtilisin/kexin type 9 inhibitorInhibitor—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Hypercholesterolemia, autosomal dominant, 3
0.82
Cardiovascular disorder
0.73
Coronary artery disorder
0.73
Metabolic disease
0.72
Inherited lipid metabolism disorder
0.72
Hypercholesterolemia, familial, 1
0.57
Coronary atherosclerosis
0.57

Drugs and mechanisms are from ChEMBL CHEMBL2929 (CC BY-SA 3.0). Gene name, function (UniProt Q8NBP7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.